Pharmaceutical companies often provide gifts and payments to doctors and other health professionals. Such support is associated with greater prescribing of promoted medicines,1 including more expensive drugs without advantages compared with standard treatment.2
- 1. Mitchell AP, Trivedi NU, Gennarelli RL, et al. Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review. Ann Intern Med 2021; 174: 353‐361.
- 2. Hartung DM, Johnston K, Cohen DM, et al. Industry payments to physician specialists who prescribe repository corticotropin. JAMA Netw Open 2018; 1: e180482.
- 3. Robertson J, Moynihan R, Walkom E, et al. Mandatory disclosure of pharmaceutical industry‐funded events for health professionals. PLoS Med 2009; 6: e1000128.
- 4. Lisa P, Emily AK, Lisa B. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study. BMJ Open 2019; 9: e024928.
- 5. Woodward C. New US law applies “sunshine” to physician payments and gifts from drug, device industries. CMAJ 2010; 182: E467‐E468.
- 6. Ozieranski P, Saito H, Rickard E, et al. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self‐regulation, public regulation, and transparency. Global Health 2023; 19: 14.
- 7. Mulinari S, Martinon L, Jachiet PA, Ozieranski P. Pharmaceutical industry self‐regulation and non‐transparency: country and company level analysis of payments to healthcare professionals in seven European countries. Health Policy 2021; 125: 915‐922.
- 8. Sullivan T. Sunshine Act takes effect in South Korea. Policy & Medicine, 4 May 2018. https://www.policymed.com/2017/08/sunshine‐act‐takes‐effect‐in‐south‐korea.html (viewed Aug 2023).
- 9. MacDonald N. Under the influence? Inside New Zealand's first disclosure of drug company payments to health professionals. Stuff, 12 Mar 2023. https://www.stuff.co.nz/national/health/131175559/under‐the‐influence‐inside‐new‐zealands‐first‐disclosure‐of‐drug‐company‐payments‐to‐health‐professionals (viewed Aug 2023).
- 10. Jones L. Financial support provided to male and female physicians by pharmaceutical companies in New Zealand: a cross‐sectional study. Med J Aust 2023; 219: 275‐277.
- 11. Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between physician characteristics and payments from industry in 2015–2017: observational study. BMJ Open 2019; 9: e031010.
- 12. Goupil B, Balusson F, Naudet F, et al. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ 2019; 367: l6015.
- 13. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ 2008; 336: 1402‐1403.
- 14. Mulinari S, Ozieranski, P. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts. BMJ Open 2018; 8: e023094.
- 15. Vitry A, Mintzes B. “Drugs to avoid” to improve quality use of medicines: how is Australia faring? J Pharm Policy Pract 2021; 14: 60.
- 16. Carey JL, Nader N, Chai PR, et al. Drugs and medical devices: adverse events and the impact on women's health. Clin Ther 2017; 39: 10‐22.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.